Shorter dual antiplatelet therapy may offer safety benefits in myocardial infarction patients

-

 


Three months of dual antiplatelet therapy (DAPT) was associated with signals suggesting improved survival and lower bleeding risk than 12 months of DAPT, in a real-world all-comer population of patients with myocardial infarction (MI), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

DUAL-ACS was an open-label, investigator-initiated, randomized trial. The trial was initially conducted in Scotland. However, the COVID-19 pandemic had an adverse impact on recruitment. Patients from England and New Zealand were then recruited. Eligible patients had had a type 1 MI within 12 weeks and required DAPT (aspirin and a P2Y12 inhibitor) in the opinion of the attending clinician. Patients were randomized 1:1 to either 3 or 12 months of DAPT. All patients were managed according to local clinical practice. Hospital admission statistics and mortality were obtained through routinely collected health records data. The primary endpoint was all-cause mortality.

A total of 5,052 patients were randomized who had a mean age of 63 years and 27% were female. Following the index admission, 23% received medical management only, 70% underwent percutaneous coronary intervention and 6% had coronary artery bypass graft surgery.

After follow-up of 15 months, the primary endpoint of all-cause mortality occurred in 2.7% of patients in the 3-month DAPT group and 3.4% of patients in the 12-month DAPT group (hazard ratio [HR] 0.78; 95% confidence interval [CI] 0.57 to 1.07; p=0.1232) with no difference in cardiovascular death or non-fatal MI (HR 1.04; 95% CI 0.87 to 1.26; p=0.6149).

Fatal and non-fatal major bleeding occurred in 3.2% of patients in the 3-month DAPT group and 4.0% of patients in the 12-month DAPT group (HR 0.78; 95% CI 0.58 to 1.06; p=0.0977).

In conclusion, Professor Newby said: "This all-comer real-world trial recruited only 30% of the planned participants and was unable to address the primary question definitively. However, there was no evidence that DAPT given for 12 months conferred any additional benefit. Indeed, the trends for lower mortality and bleeding risk with 3 months of DAPT are consistent with prior meta-analyses and suggest that limiting DAPT duration to 3 months may be safer in a real-world contemporary population."

 #ResearchChemistry, #ChemicalInnovation, #Science, #ScienceResearch, #ScientificResearch, #ResearchAndDevelopment, #ChemistryEducation, #ChemistryExperiments, #ChemistryLab, #ChemistryStudents, #ChemistryStudy, #OrganicChemistry, #InorganicChemistry, #PhysicalChemistry, #AnalyticalChemistry, #Biochemistry, #MaterialsChemistry, #TheoreticalChemistry, #AppliedChemistry, #MedicinalChemistry

Comments

Post a Comment

Popular posts from this blog

Avoiding prostate cancer screening increases risk of death

-
Image
  Men who consistently avoid prostate cancer screening appointments face a disproportionately higher risk of dying from the disease, finds research identifying a new high-risk group. An analysis of data from across seven countries from the world's largest prostate cancer screening study, the European Randomized study of Screening for Prostate Cancer (ERSPC), is presented this weekend at the European Association of Urology (EAU) Congress in Madrid. Prostate cancer is the most common form of cancer in men in 112 countries, with prevalence expected to double by 2040. If introduced on a national scale, prostate cancer screening programmes that measure levels of prostate-specific antigen (PSA) in the blood have the potential to give men earlier access to treatment, a better chance of being cured. They can also prevent costly treatment associated with advanced prostate cancer. Long-term follow-up data from the ERSPC consistently report that PSA screening programmes can lead to a 20% re...
Read more

EchoBack CAR T-cells could be a game changer in cancer immunotherapy

-
Image
  Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made this concept a reality, crafting what they have named the "EchoBack CAR T-cell," which could soon be a game changer in the field of cancer immunotherapy . The work, published in the scientific journal Cell, is a groundbreaking new approach that could overcome major obstacles in treating tumors that are not usually candidates for immunotherapy, while keeping healthy tissue safe. Chimeric antigen receptor (CAR) T-cell therapy is a promising field of cancer treatment that has shown great success in treating bloodborne cancers such as leukemia. It is a highly customized therapy in which cancer-fighting T-cells are drawn directly from the blood of a patient and given genetic modifications to enhance their ability to target and kill cancerous cells. The USC Alfred E. Mann Department ...
Read more

The Role of Analytical Chemistry in Industry and Manufacturing

-
Image
Industry and the manufacturing sector use multiple analytical chemical methods, whether for new product development, processing, or quality control. This article outlines the research to be presented at Pittcon on the advances being made in analytical chemistry and their application in industry and manufacturing. Spectroscopy is a valuable analytical tool for a wide range of sectors. Several talks will focus on Raman spectroscopy as a highly versatile analytical tool, which can be used in chemical processing from laboratory to manufacturing. Raman spectroscopy’s use in polymer science to measure and control chemical processes is a particular focus. The technique is becoming increasingly relevant as chemical manufacturing expands to include new developments such as batch reactions, microreactors, flow synthesis, and continuous processes. Pittcon will hear examples of using Raman spectroscopy to improve process efficiency and predict reaction end-times and physical properties of chemical...
Read more